Exelixis (EXEL) Common Equity (2010 - 2026)
Exelixis (EXEL) posted quarterly Common Equity of $1.9 billion for Q2 2026, down 9.16% year-over-year from $2.1 billion in Q2 2025, and down 10.44% quarter-over-quarter from $2.2 billion in Q1 2026.
Analysis
Exelixis (EXEL) Common Equity (2010 - 2026) Analysis & Trends
Exelixis' Common Equity history runs 17 years deep, the most recent figure standing at $1.9 billion for Q2 2026.
- In Q2 2026, Common Equity fell 9.16% year-over-year to $1.9 billion; the TTM figure through Apr 2026 stood at $1.9 billion (down 9.16% YoY), while the FY2026 annual figure was $2.2 billion, down 3.69% from the prior year.
- Common Equity for Q2 2026 stood at $1.9 billion, down from $2.2 billion in the prior quarter.
- The five-year high for Common Equity was $2.6 billion in Q1 2023, with the low at $1.9 billion in Q2 2026.
- The 5-year median for Common Equity is $2.3 billion (2023), against an average of $2.3 billion.
- The sharpest annual moves came in 2022 and 2024: Common Equity gained 20.02% in 2022, then decreased 16.72% in 2024.
- Exelixis' Common Equity stood at $2.5 billion in 2022, then decreased by 9.02% to $2.3 billion in 2023, then gained by 0.51% to $2.3 billion in 2024, then slipped by 5.04% to $2.2 billion in 2025, then slipped by 10.41% to $1.9 billion in 2026.
- Business Quant data shows EXEL's Common Equity at $1.9 billion in Q2 2026, $2.2 billion in Q1 2026, and $2.2 billion in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.42 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 6.76 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.61 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.17 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.79 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 1.84 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 1.84 Bn |
| Apr 3, 2026 | 1.94 Bn |
| Jan 2, 2026 | 2.16 Bn |
| Oct 3, 2025 | 2.16 Bn |
| Jul 4, 2025 | 2.03 Bn |
| Apr 4, 2025 | 2.13 Bn |
| Jan 3, 2025 | 2.24 Bn |
| Sep 27, 2024 | 2.28 Bn |
| Jun 28, 2024 | 2.12 Bn |
| Mar 29, 2024 | 2.13 Bn |
| Dec 29, 2023 | 2.26 Bn |
| Sep 29, 2023 | 2.35 Bn |
| Jun 30, 2023 | 2.53 Bn |
| Mar 31, 2023 | 2.56 Bn |
| Dec 30, 2022 | 2.49 Bn |
| Sep 30, 2022 | 2.49 Bn |
| Jul 1, 2022 | 2.39 Bn |
| Apr 1, 2022 | 2.29 Bn |
| Dec 31, 2021 | 2.21 Bn |
| Oct 1, 2021 | 2.11 Bn |